Cargando…

CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development

The SLAM family receptors contribute to diverse aspects of lymphocyte biology and signal via the small adaptor molecule SAP. Mutations affecting SAP lead to X-linked lymphoproliferative syndrome Type 1, a severe immunodysregulation characterized by fulminant mononucleosis, dysgammaglobulinemia, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Bonnie, Gomez-Rodriguez, Julio, Preite, Silvia, Garrett, Lisa J., Harper, Ursula L., Schwartzberg, Pamela L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892526/ https://www.ncbi.nlm.nih.gov/pubmed/27258160 http://dx.doi.org/10.1371/journal.pone.0156072

Ejemplares similares

CRISPR-Mediated Slamf1(Δ/Δ) Slamf5(Δ/Δ) Slamf6(Δ/Δ) Triple Gene Disruption Reveals NKT Cell Defects but Not T Follicular Helper Cell Defects
por: Hu, Joyce K., et al.
Publicado: (2016)

Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors
por: Wang, Ninghai, et al.
Publicado: (2015)

Responses to Microbial Challenges by SLAMF Receptors
por: van Driel, Boaz Job, et al.
Publicado: (2016)

Migration of Myeloid Cells during Inflammation Is Differentially Regulated by the Cell Surface Receptors Slamf1 and Slamf8
por: Wang, Guoxing, et al.
Publicado: (2015)

SLAMF6 compartmentalization enhances T cell functions
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2022)

SLAMF6 clustering is required to augment T cell activation
por: Dragovich, Matthew A., et al.
Publicado: (2019)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Clinical impact of serum soluble SLAMF7 in multiple myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2018)

The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis
por: Gonçalves-Carneiro, Daniel, et al.
Publicado: (2017)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

SLAMF6 is associated with the susceptibility and severity of rheumatoid arthritis in the Chinese population
por: Xia, Guodong, et al.
Publicado: (2022)

SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis
por: Wu, Yongjian, et al.
Publicado: (2023)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
por: Chu, Emily, et al.
Publicado: (2023)

SAP-Dependent and -Independent Regulation of Innate T Cell Development Involving SLAMF Receptors
por: De Calisto, Jaime, et al.
Publicado: (2014)

Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
por: He, Yuan, et al.
Publicado: (2019)

SLAMF1 Promotes Methotrexate Resistance via Activating Autophagy in Choriocarcinoma Cells
por: Shi, Dazun, et al.
Publicado: (2020)

SLAMF Receptor Expression Identifies an Immune Signature That Characterizes Systemic Lupus Erythematosus
por: Humbel, Morgane, et al.
Publicado: (2022)

SLAMF1 contributes to cell survival through the AKT signaling pathway in Farage cells
por: Yoon, Heejei, et al.
Publicado: (2020)

Evidence for the loss and recovery of SLAMF9 during human evolution: implications on Dollo’s law
por: Murphy, Maegan K., et al.
Publicado: (2021)

Advances in Understanding the Roles of CD244 (SLAMF4) in Immune Regulation and Associated Diseases
por: Sun, Lin, et al.
Publicado: (2021)

SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers
por: Zhang, Qun, et al.
Publicado: (2021)

SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity
por: O’Connell, Patrick, et al.
Publicado: (2022)

Strong prognostic value of SLAMF7 protein expression in patients with lymph node-positive breast cancer
por: Assidi, Mourad
Publicado: (2022)

The Receptor Slamf1 on the Surface of Myeloid Lineage Cells Controls Susceptibility to Infection by Trypanosoma cruzi
por: Calderón, Jossela, et al.
Publicado: (2012)

The Expression of the Hepatocyte SLAMF3 (CD229) Receptor Enhances the Hepatitis C Virus Infection
por: Cartier, Flora, et al.
Publicado: (2014)

Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression
por: Marcq, Ingrid, et al.
Publicado: (2013)

SLAMF1 is required for TLR4-mediated TRAM-TRIF–dependent signaling in human macrophages
por: Yurchenko, Maria, et al.
Publicado: (2018)

The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5
por: Radomir, Lihi, et al.
Publicado: (2021)

SLAMF8 Downregulates Mouse Macrophage Microbicidal Mechanisms via PI3K Pathways
por: Romero-Pinedo, Salvador, et al.
Publicado: (2022)

SLAMF8, a potential new immune checkpoint molecule, is associated with the prognosis of colorectal cancer
por: Zhang, Yaping, et al.
Publicado: (2023)

Peptide derived from SLAMF1 prevents TLR4-mediated inflammation in vitro and in vivo
por: Nilsen, Kaja Elisabeth, et al.
Publicado: (2023)

The Minor Variant of the Single-Nucleotide Polymorphism rs3753381 Affects the Activity of a SLAMF1 Enhancer
por: Putlyaeva, L.V., et al.
Publicado: (2017)

Integrated DNA methylation and gene expression analysis identifies SLAMF7 as a key regulator of atherosclerosis
por: Xia, Zhangyong, et al.
Publicado: (2018)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
por: Campbell, Kerry S., et al.
Publicado: (2018)

重型再生障碍性贫血患者SLAMF6表达状态的初步研究
Publicado: (2018)

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
por: Danhof, Sophia, et al.
Publicado: (2021)

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.
por: Bose, Prithviraj, et al.
Publicado: (2023)

LMP1(+)SLAMF1(high) cells are associated with drug resistance in Epstein-Barr virus-positive Farage cells
por: Yoon, Heejei, et al.
Publicado: (2017)

A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells
por: Yigit, Burcu, et al.
Publicado: (2016)

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling
por: Taniwaki, Masafumi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7uq3k8dkon61h9pqmfn6qruc7o